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Abstract 
Osteonecrosis of the jaw (ONJ) is an adverse effect of nitrogen-containing bisphosphonates. Advancing 
age, intravenous administration of zoledronic acid (ZOL), history of dento-alveolar surgery, and 
concomitant systemic diseases such as diabetes are known as risk factors for developing ONJ. However, 
despite numerous studies, the exact pathophysiology remains unclear and management strategies are 
largely anecdotal. Once-yearly intravenously administered 5 mg ZOL was approved by the US Food and 
Drug Administration in 2007 for the treatment of osteoporosis and its efficacy with 3 year-regimen had 
been recently been proven in preventing new clinical fracture. Although occurrences of ONJ have been 
reported to be rare with this drug administration, available data is very limited and long-term outcomes 
are lacking. We present a case of ONJ identified in an osteopenic patient with an intermittent but long 
standing sore mouth related to exposed mandibular bone. Once-yearly infusion of zoledronic acid used in 
the treatment of osteopenia may contribute to the spontaneous development of ONJ, especially in those 
presenting with multiple comorbidity factors. This report suggests the importance of health care 
professionals keeping abreast of new developments in this area and providing appropriate information to 
their patients. 
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ABSTRACT 
Osteonecrosis of the jaw (ONJ) is an adverse 
effect of nitrogen-containing bisphosphonates. 
Advancing age, intravenous administration of 
zoledronic acid (ZOL), history of dento-alveolar 
surgery, and concomitant systemic diseases 
such as diabetes are known as risk factors for 
developing ONJ. However, despite numerous 
studies, the exact pathophysiology remains un- 
clear and management strategies are largely an- 
ecdotal. Once-yearly intravenously administered 
5 mg ZOL was approved by the US Food and 
Drug Administration in 2007 for the treatment of 
osteoporosis and its efficacy with 3 year-regi- 
men had been recently proven in preventing 
new clinical fracture. Although occurrences of 
ONJ have been reported to be rare with this drug 
administration, available data is very limited and 
long-term outcomes are lacking. We present a 
case of ONJ identified in an osteopenic patient 
with an intermittent but long standing sore 
mouth related to exposed mandibular bone. 
Once-yearly infusion of zoledronic acid used in 
the treatment of osteopenia may contribute to 
the spontaneous development of ONJ, espe- 
cially in those presenting with multiple comor- 
bidity factors. This report suggests the impor- 
tance of health care professionals keeping 
abreast of new developments in this area and 
providing appropriate information to their pa- 
tients. 
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1. INTRODUCTION 
Osteonecrosis of the jaw (ONJ) was first reported as 
non-healing tooth extraction sites in cancer patients tak- 
ing nitrogen-containing bisphosphonates (NBPs) in 2003 
[1]. Emerging cases of ONJ related to a wider variety of 
medication use in osteoporosis such as Denosmub have 
led to the introduction of new terminology “antiresorp- 
tive agent-induced ONJ, “ARONJ” to replace bisphospho- 
nate-related ONJ, “BRONJ”. Incidence of ARONJ is 
estimated as small as 0.1% based on current available 
evidence [2]. The risk factors for developing ARONJ 
include advancing age, intravenous administration of 
NBPs (especially zoledronic acid: ZOL), history of den- 
toalveolar surgery, and concomitant systemic diseases 
such as diabetes. Despite numerous studies, the exact 
pathophysiology remains unclear and management strate- 
gies are largely anecdotal. 
Once-yearly intravenously administered 5 mg ZOL 
was approved by the US Food and Drug Administration 
in August 2007 for the treatment of osteoporosis. Its ef- 
ficacy with 3 year-regimen has been proven significant in 
preventing new clinical fracture [3]. Although occur- 
rences of ONJ have been reported to be rare [4], avail- 
able data are very limited and long-term outcomes are 
lacking. 
We present a case of ONJ identified in the United 
States, where a patient suffered an intermittent but long 
standing sore mouth related to exposed mandibular bone. 
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2. CASE SUMMARY 
A 66-year-old female presented with sore mouth of-
duration of three weeks and exposed mandibular bone. 
The patient denied any history of obvious trauma to the 
affected area. Her medical history was significant for 
diabetes mellitus type1, hypertension, hypothyroidism, 
breast cancer, depression, osteoarthritis and osteopenia. 
She was taking aspirin, insulin, levothyroxine, bupropion, 
losartan, letrozole, atorvastatin and vitamin B12. Her 
breast cancer was treated by lumpectomy followed by 
chemotherapy. She denied history of breast cancer-re- 
lated bisphosphonate therapy, however she was treated 
with once-yearly infusion of 5 mg ZOL for osteopenia 
the last two consecutive years. 
Intraoral examination revealed 8 × 5 mm oval shaped 
ulcer with exposed bone and significant erythematous 
surround on the left posterior mandibular torus (Figures 
1 and 2). There were no abnormal extraoral manifesta- 
tions or radiographic findings noted. Based on clinical 
diagnosis of BRONJ and because the pain was occa- 
sional, management was palliative and no surgical inter- 
vention was rendered. The use of antibacterial oral rinse 
(0.12% chlorohexidine gluconate) along with maintain- 
ing good oral hygiene and diabetes control (Patient re- 
ports consistent hemoglobin A1C of 9%.) was advised 
for the patient. At the 2 weeks re-evaluation, the oral 
lesion was still present but pain-free. We recommended 
periodic follow-up at our clinic in addition to notifying 
her physician regarding her BRONJ. 
One month later, our patient presented to the emer- 
gency clinic complaining of recurring severe pain and 
difficulty speaking associated with a tongue lesion. In- 
traorally, a mobile sequestra in the same area of the man- 
dible and a traumatic ulceration on the adjacent tongue 
were noted. Healing mucosa and mild bleeding were 
visible underling the sequestra. At this time the sequestra 
 
 
Figure 1. Occlusal view of the mandible showing exposed 
necrotic bone on the left posterior lingual tori. 
 
Figure 2. Mirror image showing exposed bone with 
inflammation in the surrounding area. 
 
was removed under local anesthesia and the patient was 
instructed to continue using antibacterial oral rinse and 
follow-up. Complete healing of both lesions was ob- 
served in 3 weeks. The patient remains without signs and 
symptoms of recurrence at 12 months. 
3. DISCUSSION 
Clinical manifestations in our patient were typical for 
BRONJ. Dentoalveolar surgery such as tooth extraction 
is a common precipitating factor, yet, as seen in our case, 
up to 30% of BRONJ cases can occur spontaneously 
without known history of trauma to the affected area [5]. 
The mandible is affected more often than the maxilla, 
especially in the area of posterior torus covered by thin 
mucosa. Pain, swelling and fistula formation arecommon 
manifestations noted at the time of diagnosis. Jaw frac-
ture may occur in severe cases. Radiographic finding 
such as diffused osteolytic lesions may not show unless 
in an advanced case, however, it is difficult todifferenti-
ate from other chronic conditions such as osteomyelitis 
or osteoradionecrosis [6]. 
Our patient had multiple other known risk factors for 
developing ONJ: advancing age (older than 65 years), a 
history of malignancy, diabetes and chemotherapy [7,8]. 
IV administration of high potent NBPs particularly ZOL 
used in cancer patients is a major contributing factor for 
ONJ, however, our patient had no history of using such 
agents in that treatment regimen. Systemic conditions 
such as DM or chronic use of chemotherapeutic agents 
can decrease the inflammatory response and, as a result, 
increase the risk of ONJ. The negative impact of diabetes 
on oral health is well-established. Delayed healing and 
susceptible infection in patients with uncontrolled diabe- 
tes are always of concern for oral health care providers. 
The higher incidence of DM in patients with BRONJ 
compared with patients without BRONJ, potentially due 
to a compromised microvasculature and endothelial cell 
dysfunction, has been reported [9]. In our case, the pa- 
tient’s A1C was consistently around 9.0% during our 
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observation. We believe that prolonged bone exposure 
was related to her diabetes condition. 
It is noteworthy that our patient is taking Letrozole. 
Letrozole is an aromatase inhibitor used inthe treatment 
of hormonally-responsive breast cancer following sur- 
gery. Letrozole has antiandrogen effects and is a poten- 
tial inhibitor of epithelial growth factor [10]. Although 
the exact etiology of BRONJ remains unclear, over sup- 
pression of bone turnover, inhibited angiogenesis and 
direct damage to oral mucosa have been considered to 
play important roles particularly with ZOL [11]. Letroni- 
dazole could further compromise the vasculature and 
oxygen perfusion in the jaw bone exacerbating the ad- 
verse effects of ZOL. 
Due to unpredictable healing outcomes in patients who 
developed BRONJ, the treatment is generally conserva- 
tive. Invasive treatment such as surgical local debride- 
ment of the affected area is usually reserved for severe 
cases. Depending on the extent of infection, systemic 
antibiotics such as penicillin VK or amoxicillin and/or 
topical antibacterial oral suspension may be prescribed. 
Infection was localized in our patient case, therefore, the 
management was focused on maintenance of optimal oral 
hygiene and control of her diabetes. The concept of drug 
holidays in an attempt to reduce the risk of ONJ for pa- 
tients planned for dento-alveolar surgery is controver- 
sial [8,12]. Our patient had the third infusion of 5 mg 
ZOL three months after complete healing of her oral le- 
sions. The comprehensive dental treatment plan was 
modified as a precautionary measure. 
4. CONCLUSION 
BRONJ as a disease process has multiple contributing 
risk factors. Although reported to be low, the incidence 
of BRONJ in osteopenic patients taking the once-yearly 
infusion of 5 mg ZOL may be higher than previously 
thought, especially in those with multiple comorbidities. 
Coordinated efforts between physician and oral health 
care provider related to the risks and benefits of continu-
ing antiresorptive therapy are imperative. All health care 
providers are encouraged to keep abreast of new devel- 
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